Prothena® is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases.
We are committed to developing novel and transformative medicines to create a better future for people in need of new treatment options. Our portfolio aims to impact neurodegenerative and rare peripheral amyloid diseases, affecting millions of people worldwide.